Back to New York

S6758 • 2025

Requires practitioners to discuss certain risks with a patient who is being prescribed a controlled substance or an opioid analgesic

Requires practitioners to discuss certain risks with a patient who is being prescribed a controlled substance or an opioid analgesic

Passed Legislature

This bill passed both chambers and reached final enrollment, even if later executive action is not shown here.

Sponsor
Nathalia Fernandez
Last action
2026-05-29
Official status
In Assembly Committee
Effective date
Not listed

Plain English Breakdown

Using official source text because the generated explanation was unavailable or could not be confirmed against the official bill text.

Requires practitioners to discuss certain risks with a patient who is being prescribed a controlled substance or an opioid analgesic

Requires practitioners to discuss certain risks with a patient who is being prescribed a controlled substance or an opioid analgesic Requires practitioners to discuss certain risks with a patient who is being prescribed a schedule II controlled substance or an opioid analgesic; requires the department of health to develop practitioner guidelines.

What This Bill Does

  • Requires practitioners to discuss certain risks with a patient who is being prescribed a controlled substance or an opioid analgesic Requires practitioners to discuss certain risks with a patient who is being prescribed a schedule II controlled substance or an opioid analgesic; requires the department of health to develop practitioner guidelines.

Limits and Unknowns

  • This entry is temporarily using official source text because the generated explanation could not be confirmed against the official bill text during the last sync.

Bill History

  1. 2026-05-29 Senate

    PASSED SENATE

  2. 2026-05-29 Senate

    DELIVERED TO ASSEMBLY

  3. 2026-05-29 Assembly

    REFERRED TO HEALTH

  4. 2026-05-14 Senate

    ADVANCED TO THIRD READING

  5. 2026-05-13 Senate

    2ND REPORT CAL.

  6. 2026-05-12 Senate

    1ST REPORT CAL.1095

  7. 2026-05-05 Senate

    AMEND AND RECOMMIT TO HEALTH

  8. 2026-05-05 Senate

    PRINT NUMBER 6758B

  9. 2026-01-16 Senate

    AMEND AND RECOMMIT TO HEALTH

  10. 2026-01-16 Senate

    PRINT NUMBER 6758A

  11. 2026-01-07 Senate

    REFERRED TO HEALTH

  12. 2025-03-24 Senate

    REFERRED TO HEALTH

Official Summary Text

Requires practitioners to discuss certain risks with a patient who is being prescribed a controlled substance or an opioid analgesic
Requires practitioners to discuss certain risks with a patient who is being prescribed a schedule II controlled substance or an opioid analgesic; requires the department of health to develop practitioner guidelines.

Current Bill Text

Read the full stored bill text
S T A T E   O F   N E W   Y O R K
        ________________________________________________________________________

                                          6758

                               2025-2026 Regular Sessions

                                    I N  S E N A T E

                                     March 24, 2025
                                       ___________

        Introduced by Sen. FERNANDEZ -- read twice and ordered printed, and when
          printed to be committed to the Committee on Health

        AN  ACT to amend the public health law, in relation to requiring practi-
          tioners  to  discuss  certain  risks  with  a  patient  who  is  being
          prescribed a controlled substance or an opioid analgesic

          THE  PEOPLE OF THE STATE OF NEW YORK, REPRESENTED IN SENATE AND ASSEM-
        BLY, DO ENACT AS FOLLOWS:

     1    Section 1. Subdivision 9 of section 3331 of the public health law,  as
     2  added by chapter 732 of the laws of 2022, is amended to read as follows:
     3    9.  (a)  When  a  patient seeks treatment for any neuromusculoskeletal
     4  condition that causes pain, where a practitioner  considers  [an  opioid
     5  treatment]  PRESCRIPTION  OF  A SCHEDULE II CONTROLLED SUBSTANCE FOR THE
     6  TREATMENT OF PAIN OR ANY OTHER OPIOID DRUG WHICH IS A PRESCRIPTION  DRUG
     7  FOR  ACUTE  OR  CHRONIC  PAIN  AND  AGAIN  PRIOR  TO  ISSUING  THE THIRD
     8  PRESCRIPTION OF THE COURSE OF TREATMENT, the practitioner shall  consid-
     9  er,  discuss  with  the  patient  AS  SET FORTH IN PARAGRAPH (B) OF THIS
    10  SUBDIVISION, and, as appropriate, refer or prescribe  non-opioid  treat-
    11  ment  alternatives,  based  on  the practitioner's clinical judgment and
    12  following generally accepted national professional or  treatment  guide-
    13  lines, and consistent with patient preference and consent, before start-
    14  ing a patient on opioid treatment. For the purposes of this subdivision,
    15  non-opioid  treatment  alternatives  include,  but  are  not limited to:
    16  acupuncture, chiropractic, massage therapy,  physical  therapy,  occupa-
    17  tional  therapy,  cognitive  behavioral therapy, non-opioid medications,
    18  interventional treatments and non-clinical activities such as  exercise.
    19  The  practitioner  shall inform the patient that some treatments may not
    20  be covered by the patient's health coverage.
    21    (b) A PRACTITIONER SHALL DISCUSS WITH THE PATIENT,  OR  THE  PATIENT'S
    22  PARENT  OR GUARDIAN IF THE PATIENT IS UNDER EIGHTEEN YEARS OF AGE AND IS
    23  NOT AN EMANCIPATED MINOR, THE RISKS  ASSOCIATED  WITH  THE  DRUGS  BEING
    24  PRESCRIBED, INCLUDING BUT NOT LIMITED TO:

         EXPLANATION--Matter in ITALICS (underscored) is new; matter in brackets
                              [ ] is old law to be omitted.
                                                                   LBD11164-01-5
        S. 6758                             2

     1    (I)  THE  RISKS OF ADDICTION AND OVERDOSE ASSOCIATED WITH OPIOID DRUGS
     2  AND THE DANGERS OF TAKING OPIOID DRUGS WITH ALCOHOL, BENZODIAZEPINES AND
     3  OTHER CENTRAL NERVOUS SYSTEM DEPRESSANTS;
     4    (II) THE REASONS WHY THE PRESCRIPTION IS NECESSARY;
     5    (III) ALTERNATIVE TREATMENTS THAT MAY BE AVAILABLE; AND
     6    (IV)  THE RISKS ASSOCIATED WITH THE USE OF THE DRUGS BEING PRESCRIBED,
     7  SPECIFICALLY THAT OPIOIDS ARE  HIGHLY  ADDICTIVE,  EVEN  WHEN  TAKEN  AS
     8  PRESCRIBED,  THAT THERE IS A RISK OF DEVELOPING A PHYSICAL OR PSYCHOLOG-
     9  ICAL DEPENDENCE ON THE CONTROLLED  SUBSTANCE,  AND  THAT  THE  RISKS  OF
    10  TAKING  MORE  OPIOIDS  THAN PRESCRIBED, OR MIXING SEDATIVES, BENZODIAZE-
    11  PINES  OR  ALCOHOL  WITH  OPIOIDS,  CAN  RESULT  IN  FATAL   RESPIRATORY
    12  DEPRESSION.
    13    (C)  THE  DEPARTMENT SHALL DEVELOP AND MAKE AVAILABLE TO PRACTITIONERS
    14  GUIDELINES FOR THE DISCUSSION REQUIRED BY THIS SUBDIVISION.
    15    (D) The requirements of this subdivision shall not apply for  patients
    16  being  treated  under  any of the following circumstances:  treatment of
    17  cancer; hospice or other end-of-life care; post-surgery treatment  imme-
    18  diately  following a surgical procedure; or in a medical emergency.  For
    19  purposes of this subdivision, "medical emergency" means an acute  injury
    20  or illness that poses an immediate risk to a person's life or health.
    21    §  2.  Paragraph  (a)  of  subdivision 3 of section 3309 of the public
    22  health law is amended by adding a new  subparagraph  (vii)  to  read  as
    23  follows:
    24    (VII) "OPIOID ANALGESICS" MEANS THE MEDICINES BUPRENORPHINE, BUTORPHA-
    25  NOL,   CODEINE,  HYDROCODONE,  HYDROMORPHONE,  LEVORPHANOL,  MEPERIDINE,
    26  METHADONE, MORPHINE, NALBUPHINE,  OXYCODONE,  OXYMORPHONE,  PENTAZOCINE,
    27  PROPOXYPHENE AS WELL AS THEIR BRAND NAMES, ISOMERS AND COMBINATIONS.
    28    §  3. Subdivision 7 of section 3309 of the public health law, as added
    29  by chapter 803 of the laws of 2021, is amended to read as follows:
    30    7. [With] FOR the first OPIOID ANALGESIC prescription [to a particular
    31  patient] of [an opioid of each] A CALENDAR year THAT IS GREATER  THAN  A
    32  ONE WEEK'S SUPPLY, for use in a setting other than a general hospital or
    33  nursing  home  under  article  twenty-eight  of this chapter or facility
    34  under article thirty-one of the mental hygiene law, or  when  a  practi-
    35  tioner is prescribing a controlled substance to a patient under the care
    36  of  hospice as defined by section four thousand two of this chapter, the
    37  prescriber shall COUNSEL THE PATIENT  ON  THE  RISKS  OF  OVERDOSE,  AND
    38  prescribe  an  opioid  antagonist when any of the following risk factors
    39  are present: (a) a history of substance use disorder; (b) high  dose  or
    40  cumulative prescriptions that result in ninety morphine milligram equiv-
    41  alents  or higher per day; (c) concurrent use of opioids and benzodiaze-
    42  pine or nonbenzodiazepine sedative hypnotics.
    43    § 4. This act shall take effect immediately.